OpenNashEarnings

Doximity (DOCS) · Health Care

Doximity Q2 FY2027 earnings call: transcript, summary & key numbers

Results filed 5 Nov 2026 · Quarter ended 30 Sep 2026 · Call 63 min · Jeff Tangney (CEO), Matt Sonnenfeld (CFO)

Read the transcriptPress release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Doximity paired its new DoseCheck medication-safety verifier with UpToDate content in its clinical AI as more than 190 health systems bought the AI suite and pharma began buying AI search.

Doximity launched DoseCheck, a deterministic verifier that checks AI drug-dose answers against its own drug dataset, and added UpToDate to its AI answers. More than 190 health systems now buy its AI suite, including New York Presbyterian, which offers it inside its electronic health record. A new patient context feature lets doctors ask chart-specific questions. On the pharma side, 16 of the top 20 companies have bought AI search, a product that places advertising inside AI answers.

Management wants one platform for clinical decision support, documentation and patient communication, and wants pharma search budgets to follow. It plans biddable, auction-style buying for smaller advertisers, starting with pilot clients. The main tension is timing. Medical-legal review means AI search revenue should ramp gradually through calendar 2027, the pharma upfront season is unfinished, and heavy AI spend on clinicians comes before monetization.

Key numbers

Revenue · GAAP
$174.5 million

an increase of 4% year-over-year

Net income · GAAP
$34.7 million

versus $62.1 million

Diluted EPS · GAAP
$0.18

versus $0.31

Non-GAAP diluted EPS · non-GAAP
$0.36

versus $0.45

GAAP operating income · GAAP
$43.9M

versus $63,681

GAAP gross margin · GAAP
85.5%

versus 90.3%

Operating cash flow · GAAP
$93.3 million

a decrease of 1% year-over-year

Free cash flow · non-GAAP
$91.3 million

a decrease of less than 1% year-over-year

Segment or metricValueChange
Health systems purchasing the AI suiteMore than 190up from 165 last quarter
Quarterly active workflow prescribers growth34 %year-on-year, accelerating from last quarter
Overall net revenue retention103%top 20 hospital and pharma customers at 106 %
Customers with more than $500,000 in annual spend124grew 3 % year-over-year
Top 20 pharma companies that purchased AI search16 of the top 20three more in contracting
Where each number comes from
  • Revenue: “Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year.”
  • Net income: “Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%.”
  • Diluted EPS: “Diluted net income per share was $0.18, versus $0.31, while non-GAAP diluted net income per share was $0.36, versus $0.45.”
  • Non-GAAP diluted EPS: “Diluted net income per share was $0.18, versus $0.31, while non-GAAP diluted net income per share was $0.36, versus $0.45.”
  • GAAP operating income: “GAAP operating income | $43,922 | $63,681 | $77,565 | $118,198”
  • GAAP gross margin: “GAAP gross margin | 85.5% | 90.3% | 85.2% | 89.8% Non-GAAP gross margin | 87.8% | 91.9% | 87.6% | 91.6%”
  • Operating cash flow: “Operating cash flow of $93.3 million, versus $93.9 million, a decrease of 1% year-over-year, and free cash flow of $91.3 million, versus $91.6 million”
  • Free cash flow: “Operating cash flow of $93.3 million, versus $93.9 million, a decrease of 1% year-over-year, and free cash flow of $91.3 million, versus $91.6 million”
  • Health systems purchasing the AI suite: “More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.”
  • Quarterly active workflow prescribers growth: “Quarterly active workflow prescribers, which includes our AI users, grew 34 % year-on-year to record highs, accelerating from last quarter.”
  • Overall net revenue retention: “our top 20 hospital and pharma customers produced net revenue retention or NRR of 106 % with overall NRR of 103%.”
  • Customers with more than $500,000 in annual spend: “Customers with greater than $500,000 in annual spend represented 82 % of revenue and grew 3 % year-over-year to 124.”
  • Top 20 pharma companies that purchased AI search: “16 of the top 20 pharma companies have already purchased with three more in contracting.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 FY2027vs year agovs last quarter
Revenue$174.5M+3.6%+11.4%
Operating income$43.9M−31.0%+30.5%
Net income$34.7M−44.0%+42.8%
Diluted EPS$0.18−41.9%+38.5%
Free cash flow$93.3M−0.7%+122.5%
Gross margin85.5%−4.8 pts+0.6 pts
Operating margin25.2%−12.6 pts+3.7 pts

Calculated by code from XBRL, not by the model.

Guidance check

MetricOutlook given with Q1 FY2027ReportedResult
Revenuebetween $170 million and $171 million$174.5Mabove the range

Compared with the company's own guidance, not analyst estimates, and only where the outlook and the reported figure are the same measure on the same basis. Ranges are worked out by code from the company's wording. How this works.

Outlook

MetricPeriodOutlook
Revenuefiscal third quarter ending December 31, 2026$195 million and $196 million
Adjusted EBITDAfiscal third quarter ending December 31, 2026$102.5 million and $103.5 million
Revenuefiscal year ending March 31, 2027$678 million and $683 million
Adjusted EBITDAfiscal year ending March 31, 2027$317 million and $325 million

Key takeaways

  1. AI search opens pharma's paid-search budgets

    16 of the top 20 pharma companies have bought AI search, three more are in contracting, and bookings are eight figures. Management cites a Bank of America survey in which 81 % of pharma marketers would spend incremental budget with Doximity, versus 6 % for paid search or Google.

  2. DoseCheck and UpToDate target AI accuracy concerns

    DoseCheck verifies AI drug-dose answers against Doximity's drug dataset; its study of over a quarter million queries found a 2.3 % error rate across major models. UpToDate adds proprietary point-of-care content that management says no frontier model has.

  3. Health systems adopt the AI suite and EHR access

    AI clients rose to over 190 from 165, including 10 of the top 20 hospitals, and New York Presbyterian now offers Doximity AI from its EHR. Patient context roughly doubles usage, but management says a button inside an EHR alone does not drive adoption.

  4. Telehealth and scheduling drive record workflow engagement

    Workflow prescribers grew 34 % year-on-year, and about half of the 1.8 million U.S. prescribers used Doximity last quarter. Management credits telehealth, scheduling and AI, and sees engagement growth leading to later monetization.

  5. AI search revenue should ramp slowly through 2027

    Medical-legal review can take months, so Doximity expects Q4 growth similar to Q3 and a gradual AI search ramp. It plans biddable, auction-style buying for smaller advertisers, starting with pilot clients.

Charts

Revenue$174.5M+3.6% y/yQ2 FY27
Q3 FY25: $168.6MQ3 25$168.6MQ4 FY25: $138.3M (worked out from the annual figure)Q4 25$138.3MQ1 FY26: $145.9MQ1 26$145.9MQ2 FY26: $168.5MQ2 26$168.5MQ3 FY26: $185.1MQ3 26$185.1MQ4 FY26: $145.4M (worked out from the annual figure)Q4 26$145.4MQ1 FY27: $156.6MQ1 27$156.6MQ2 FY27: $174.5MQ2 27$174.5M

Fourth quarter worked out from the annual figure.

Data
Q3 FY25$168.6M
Q4 FY25$138.3M *
Q1 FY26$145.9M
Q2 FY26$168.5M
Q3 FY26$185.1M
Q4 FY26$145.4M *
Q1 FY27$156.6M
Q2 FY27$174.5M
Diluted EPS (GAAP)$0.18−41.9% y/yQ2 FY27
Q3 FY25: $0.37Q3 25$0.37Q1 FY26: $0.27Q1 26$0.27Q2 FY26: $0.31Q2 26$0.31Q3 FY26: $0.31Q3 26$0.31Q1 FY27: $0.13Q1 27$0.13Q2 FY27: $0.18Q2 27$0.18
Data
Q3 FY25$0.37
Q1 FY26$0.27
Q2 FY26$0.31
Q3 FY26$0.31
Q1 FY27$0.13
Q2 FY27$0.18

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Operating margin25.2%−12.6 pts y/yQ2 FY27
Q3 FY25: 47.4%Q3 2547.4%Q4 FY25: 35.2%Q4 2535.2%Q1 FY26: 37.4%Q1 2637.4%Q2 FY26: 37.8%Q2 2637.8%Q3 FY26: 38.9%Q3 2638.9%Q4 FY26: 17.1%Q4 2617.1%Q1 FY27: 21.5%Q1 2721.5%Q2 FY27: 25.2%Q2 2725.2%
Data
Q3 FY2547.4%
Q4 FY2535.2%
Q1 FY2637.4%
Q2 FY2637.8%
Q3 FY2638.9%
Q4 FY2617.1%
Q1 FY2721.5%
Q2 FY2725.2%
Free cash flow$93.3M−0.7% y/yQ2 FY27
Q3 FY25: $65.2MQ3 25$65.2MQ4 FY25: $98.5MQ4 25$98.5MQ1 FY26: $62.1MQ1 26$62.1MQ2 FY26: $93.9MQ2 26$93.9MQ1 FY27: $41.9MQ1 27$41.9MQ2 FY27: $93.3MQ2 27$93.3M
Data
Q3 FY25$65.2M
Q4 FY25$98.5M
Q1 FY26$62.1M
Q2 FY26$93.9M
Q1 FY27$41.9M
Q2 FY27$93.3M

Operating cash flow minus capital expenditure, from cash flow statements.

What management said

Each quote matches the transcript word for word.

“So, you know, people don't want to go type the full patient history into a search bar. They want a suite, not a search bar, and that's what we offer them.”

Frames Doximity's product bet: an integrated suite with patient context rather than a standalone AI search box.

0:27:39 · Jeff Tangney (CEO)

“So I think that's proof that with AI search we are entering search budgets, which is about $14 billion a year in the United States, according to eMarketer, just for pharma.”

Shows management sees AI search as a move into a much larger pharma ad market than its historical media business.

0:18:12 · Jeff Tangney (CEO)

“the truth is just putting a button inside an EHR does not, in and of itself, get immediate usage. You actually have to do a bit of training and webinars.”

A candid caveat that EHR integration alone does not drive adoption without training and support.

0:41:40 · Jeff Tangney (CEO)

“Final point note, we have significant customer overlap. They have 2,500 health systems as clients. We have, you know, 190. So we see a lot of overlap between our client base, and that also creates additional synergies for us.”

Points to UpToDate as a possible distribution channel into health systems.

0:24:18 · Jeff Tangney (CEO)

“for new products, MLR review can be months and months, And we learned this, candidly, the hard way back with our vertical video product, as you may recall, a few years ago.”

Explains why management expects AI search revenue to lag signed contracts.

0:44:31 · Scott Schoenhaus (KeyBanc)

“my favorite financial metric from the quarter was our cost of revenue grew up less than half of our overall prompt volume in Q2.”

Shows AI unit economics improving as usage scales.

0:21:07 · Matt Sonnenfeld (CFO)

Analyst Q&A

  1. 0:16:38 · Brian Peterson, Raymond James · AI search

    How did AI search build this year and what could it do for Doximity's positioning into 2027?

    Jeff Tangney said top-level meetings with pharma executives are going well, a survey shows pharma marketers favoring Doximity over paid search, and biddable auction-based buying will start with pilot clients. — Jeff Tangney

  2. 0:19:17 · Brian Peterson, Raymond James · AI compute costs

    Can you unpack the AI compute efficiency measures?

    Management said cost of revenue grew at less than half the rate of prompt volume, helped by multi-model use, pre-bought capacity and its proprietary harness. — Jeff Tangney, Matt Sonnenfeld

  3. 0:21:38 · Michael Cherney, Leerink Partners · UpToDate partnership

    Why was UpToDate the right partner for Doximity's AI?

    Jeff Tangney called UpToDate the most used and trusted point-of-care reference, with content no frontier model has, and said both firms have many shared health-system clients. — Jeff Tangney

  4. 0:30:00 · Michael Cherney, Leerink Partners · Operating leverage

    What builds confidence in operating leverage beyond the efficiencies already cited?

    Matt Sonnenfeld said engagement comes before monetization, nothing in the AI investment or early AI search suggests a worse margin profile, and scaling AI search in FY28 should lift incremental margins. — Matt Sonnenfeld

  5. 0:31:45 · Ryan Daniels, William Blair · Cannibalization

    Is AI search cannibalizing other pharma sales or is it incremental?

    Jeff Tangney said it is mostly incremental, bought by separate search teams, though not provably 100 %, and Matt Sonnenfeld said all major product categories grew. — Jeff Tangney, Matt Sonnenfeld

  6. 0:34:08 · Ryan Daniels, William Blair · AI governance

    How does tighter health-system AI governance affect Doximity's advantage?

    Jeff Tangney said health systems are moving past an unregulated phase of AI, citing a Johns Hopkins data incident, and that Doximity has privacy agreements with over 300 enterprise clients. — Jeff Tangney

  7. 0:37:12 · Elizabeth Anderson, Evercore ISI · Customer ramp

    How are smaller pharma customers ramping with AI search compared with the top 20?

    Jeff Tangney said smaller accounts move faster but are being saved for the biddable tool, and Matt Sonnenfeld said available conditions have more than doubled on customer demand. — Jeff Tangney, Matt Sonnenfeld

  8. 0:40:20 · Ryan McDonald, Needham & Company · EHR integration

    What usage uplift comes from EHR integration, as at New York Presbyterian?

    Jeff Tangney said patient context roughly doubles usage, but simply adding a button in an EHR drives less usage than expected without training. — Jeff Tangney

  9. 0:42:50 · Ryan McDonald, Needham & Company · UpToDate distribution

    Can UpToDate help bring Doximity into health systems?

    Jeff Tangney said UpToDate is in virtually every U.S. health system and the partnership is multi-year, but he had no go-to-market announcement. — Jeff Tangney

  10. 0:43:58 · Scott Schoenhaus, KeyBanc · Medical-legal review

    How long does medical-legal review take and how does AI search revenue ramp after it?

    Jeff Tangney said review can take many months, as with the video product, and Matt Sonnenfeld said guidance assumes a gradual ramp through calendar 2027. — Jeff Tangney, Matt Sonnenfeld

  11. 0:46:54 · Scott Schoenhaus, KeyBanc · Growth outlook

    What does the roughly 6 % growth rate say about market growth versus Doximity's own?

    Matt Sonnenfeld said it reflects the beginnings of reacceleration but is cautious until the upfront season ends, and Jeff Tangney expects a somewhat better market next year. — Matt Sonnenfeld, Jeff Tangney

  12. 0:48:32 · Richard Close, Canaccord Genuity · Go-to-market

    Is there a separate sales force for AI search and is it bundled into upfront contracts?

    Jeff Tangney said AI search experts overlay the existing sales team, and the work is usually under a separate statement of work from the same master agreement. — Jeff Tangney

  13. 0:49:48 · Jessica Tadson, Piper Sandler · Monetization

    How is AI search monetized: enterprise subscriptions, pharma bookings or both?

    Matt Sonnenfeld said the eight-figure bookings are primarily pharma advertising, while health systems pay a nominal amount as part of the broader workflow suite. — Matt Sonnenfeld

  14. 0:51:41 · Jessica Tadson, Piper Sandler · Pharma ROI

    What are early thoughts on ROI for pharma content in AI search versus the core business?

    Management said it is too early, but expects ROI as strong as other products or better, with AI signals also improving the rest of the portfolio. — Matt Sonnenfeld

  15. 0:53:12 · Destiny Jackson, JPMorgan · Net revenue retention

    What drove lower net revenue retention and how can expansion reaccelerate?

    Matt Sonnenfeld said retention follows revenue growth and he expects reacceleration, and Jeff Tangney pointed to AI search, a stronger core portfolio and a better market. — Matt Sonnenfeld, Jeff Tangney

  16. 0:55:12 · Destiny Jackson, JPMorgan · Customer count

    Why did the count of customers above $500,000 come down?

    Matt Sonnenfeld said the second quarter is seasonally weaker for that metric because there is less upsell activity. — Matt Sonnenfeld

  17. 0:56:27 · Alan Lutz, Bank of America · Competition

    How is the competitive landscape evolving in AI search for pharma and health systems?

    Jeff Tangney said pharma interest in incremental spend with Doximity is at a high while paid search is at a low, and Doximity now operates as both a media and a search company. — Jeff Tangney

  18. 0:58:25 · Alan Lutz, Bank of America · Investment vs margins

    How does Doximity weigh high-ROI investment in AI search against keeping margins above 50 %?

    Matt Sonnenfeld said the full-year margin guide already builds in investment, and efficiency gains let Doximity keep playing offense while generating strong incremental margins. — Matt Sonnenfeld

  19. 1:01:06 · Ryan Halstead, RBC Capital Markets · Pharma budgets

    How healthy are HCP marketing budgets going into the upfront season?

    Management described a more stable environment than last year as policy uncertainty eases, though not a major reacceleration. — Matt Sonnenfeld, Jeff Tangney

Questions

What did Doximity launch or add to its AI this quarter?

It launched DoseCheck, a deterministic verifier for medication safety, and added UpToDate to its AI answers. It also rolled out a patient context feature that lets doctors ask questions grounded in a patient's chart.

How are health systems adopting Doximity's AI?

More than 190 health systems now have the AI suite, up from 165 last quarter, including 10 of the top 20 hospitals. New York Presbyterian offers it from its EHR, and patient context roughly doubles usage.

How is Doximity monetizing AI search and who is buying it?

AI search is sold mainly as a pharma advertising product, with 16 of the top 20 pharma companies purchasing and three more in contracting. Health systems pay only a nominal amount within the broader workflow suite.

What is the main risk to the AI search ramp?

Medical-legal review can take months, so management expects AI search revenue to ramp gradually through calendar 2027. The upfront season is also unfinished, so Q4 visibility is limited.

How does Doximity see its competitive position in clinical AI?

It says it leads on accuracy, with DoseCheck, a top ranking among 16 models in a Fireworks-graded benchmark and UpToDate content. It also leads on distribution through 190 health system clients and its workflow tools.

Documents

From Doximity investor relations

SEC filing

Transcript

Call recording on YouTube ↗. Official replay ↗. Timestamps jump to the moment.

0:00:00
Operator

Hello everyone. Thank you for joining us and welcome to Doximity's second quarter 2026 earnings conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I'll now hand the conference over to Perry Gold. Perry, please go ahead.

0:00:27
Perry Gold (Investor Relations)

Thank you, Operator. Hello and welcome to Doximity's Fiscal 2027 Second Quarter Earnings Call.

0:00:33

With me on the call today are Jeff Tangney, co-founder and CEO of Doximity, and Matt Sonfeld, CFO. A complete disclosure of our results can be found in our press release issued earlier today, as well as in our related Form 8K, along with a copy of our prepared remarks, all available on our website at investors .doximity .com. As a reminder, today's call is being recorded and a replay will be available on our website. As part of our comments today, we will be making forward-looking statements.

0:01:03

These statements are based on management's current views, expectations, and assumptions and are subject to various risks and uncertainties. Actual results may differ materially and we may disclaim any obligation to update any forward-looking statements or outlook. Please refer to the risk factors in our annual report on Form 10-K, any subsequent Form 10-Qs, and any other reports and filings of the SEC that may be filed from time to time, including our upcoming filing on Form 10-Q.

0:01:31

Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, November 5, 2026. Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call unless it is also done through a public disclosure, such as a press release or through the filing of a Form 8K. Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results.

0:01:58

A historical reconciliation to comparable GAAP metrics can be found in today's earnings release. Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one time in nature, and we may or may not provide updates on those metrics in the future. I would now like to turn the call over to our CEO and co-founder, Jeff Tangney. Jeff?

0:02:22
Jeff Tangney (CEO)

Thanks, Perry, and thanks everyone for joining our second quarter earnings call.

0:02:26

Today, I'll cover three things, our financials, AI accuracy, and engagement. First, our financials. Revenue was $175 million in Q2, up 4 % year-on-year and 2 % above the high end of our guidance. Even with over 6x growth year-on-year in our AI spend, our Q2-adjusted EBITDA margin was 51%, or $89 1,000,009 % above the high end of our guidance. So while this remains our AI investment year, we continue to have strong margins.

0:03:00

Okay, now to AI accuracy. It's by far the number one concern doctors have about AI. AI deals in probabilities. Patient care demands precision. All of us have had the experience of hitting refresh on an AI answer and getting a different response. Thankfully, accuracy is where we continue to lead the way. For starters, we launched DoseCheck, a deterministic verifier for medication safety. In a study of over a quarter million AI drug dose queries across all major models, we found a 2.3 % error rate.

0:03:38

What's more, 40 % of these errors are serious or even lethal. So from a million AI drug queries, 9,000 patients could get hurt. That's too many. Our dose check catches these errors using our built-in drug data set. It's painstaking work, and we're proud to do it. Second, we're excited to add UpToDate to our AI answers. Every clinical AI model has read the National Library of Medicine, which has all of the journals and guidelines, but Walter's Kluwer's UpToDate stands alone as the proprietary gold standard reference for point of care.

0:04:16

Their 7,600 physician authors provide unique advice about what to do when there isn't an RCT or randomized controlled trial to answer the question. We think this real-world medical layer is really important. And now, it's one tap away inside of Doximity. Independent tests keep confirming our lead in accuracy and safety. In September, we joined other vertical AI leaders like Harvey and Law and Sierra and Customer Service to create industry-specific benchmarks. When AI provider Fireworks graded the results, Doximity ranked first among 16 leading models, echoing our Stanford No Harm study results in July.

0:05:02

Physician input is critical to getting AI and medicine right. This quarter, we convened our Medical AI Summit, 150 physicians, chiefs and chairs from our nation's best hospitals, joined by two former U .S. Surgeons General, Dr. Vivek Murthy and Dr. Regina Benjamin, to work through how we build clinical AI responsibly together. As a physician's first company, this unique semi-annual event is our North Star and guides our roadmap. Finally, our engagement and client growth. Quarterly active workflow prescribers, which includes our AI users, grew 34 % year-on-year to record highs, accelerating from last quarter.

0:05:48

So, for the first time, approximately half of all of the 1.8 million U .S. prescribers used us last quarter as part of their workflow. Our health system client footprint continued to grow as well, up over 190 on our AI suite from 165 last quarter, including 10 of the nation's top 20 hospitals. New York Presbyterian now provides access to Doximity AI directly from its EHR, giving New York Presbyterian, Columbia, and Weill Cornell Medicine clinicians convenient access to AI-powered tools and the latest medical research within their existing workflows.

0:06:29

Over the past five years working with New York Presbyterian, we've seen firsthand why they're consistently ranked among the nation's best hospitals, and we're excited to grow our AI tool set with them. UCSD Health, the number one ranked hospital in San Diego, is another AI client and one of the first hospitals to adopt our new patient context feature. Directly from a patient's chart, our AI can read that patient's notes, labs, imaging, conditions, and coverage to give patient-specific answers and guideline-based treatment plans.

0:07:02

It's the difference between a doctor asking a general medical question and asking about the patient in front of them. Our patient context feature is now available for thousands of doctors, and their writing prompts half as long, 12 words versus our 24-word average because they no longer have to retype the chart details into a search bar. Our AI already has the labs, notes, and problem lists, so we can find the pertinent clinical details deep in their record.

0:07:32

To fit more workflows, we're opening API access to our clinical intelligence layer. If you're building time-saving tools for clinicians, we'd love to work with you. Just email us at bd at doximity .com. Last, on the pharma side, our AI search commercial offering has been well received. 16 of the top 20 pharma companies have already purchased with three more in contracting. And more than 100 clients attended our pharma AI showcase last month, our biggest turnout ever.

0:08:06

To sum up, with dose check and up to date, we lead on AI accuracy and trust. With 190 health system AI clients and patient context, we lead on distribution and integration. And with AI Search now available to our pharma clients, we're growing into a much larger market. As always, I'd like to end by thanking my Doximity teammates who continue to work incredibly hard to care for those who care for us. With that, I'll hand it over to our CFO, Matt Sonnenfeld to walk us through our financials and guidance.

0:08:44

Matt?

0:08:44
Matt Sonnenfeld (CFO)

Thanks, Jeff. Q2 was another strong quarter for Doximity, with AI usage driving accelerated adoption of our broader workflow suite. This validates our decision to expand AI investment in FY27. We also improved AI cost efficiency during the quarter, which helped drive higher than expected profitability. Turning to our top line, Q2 revenue of $174.5 million outperformed our guidance with 4 % year-over-year growth. This growth comes against a difficult year-over-year comparison versus Q2 26 when we benefited from rapid adoption of our multi-module integrated offering.

0:09:22

Revenue upside in Q2 was driven by solid performance across our product portfolio as well as growing interest in our AI search product. Positive AI search demand signals include pharma company customers purchasing on average more than two programs each and a doubling of available conditions driven by customer interest. We believe customer engagement with AI search continues to drive broader momentum across our entire pharma portfolio. In terms of customer metrics, our top 20 hospital and pharma customers produced net revenue retention or NRR of 106 % with overall NRR of 103%.

0:10:00

Customers with greater than $500,000 in annual spend represented 82 % of revenue and grew 3 % year-over-year to 124. As a reminder, these are trailing 12-month metrics. Turning to profitability, adjusted EBITDA on Q227 was $89 million and represented that 51 % margin. Our performance was split evenly between the flow-through of higher-than-expected revenue and better-than-anticipated AI efficiency. The non-gap gross margin was 88 % versus 92 % last quarter.

0:10:31

As we shared last quarter, the majority of the increase in cost of revenue reflects scaling our AI investment to support rapidly growing engagement. As a reminder, over 90 % of our incremental AI cost was for clinician usage. Even with significant engagement increases, we realized AI cost leverage. Efficiency drivers include pre-buying more capacity at favorable economics, greater multi-model usage, and continued performance gains in our proprietary harness. We're encouraged by improving AI unit economics even as we increase the accuracy and value we deliver to clinicians.

0:11:09

On a GAAP basis, stock-based compensation, or SBC, was $41 million in the quarter, or 23 % of revenue. This is consistent with the low 20 % SBC guidance provided last quarter. As a reminder, this year's SBC increase is primarily related to the FY26 grant made to our AI-focused R &D team. Excluding the grant, SBC would have been approximately 19 % of revenue in Q2. We expect the impact of the AI grant to ease in FY28.

0:11:37

Our GAAP effective tax rate was approximately 31 % in the second quarter compared to 15 % in the prior year, driven by the tax treatment of equity compensation. Our non-GAAP effective tax rate remained at 21%. In Q2, GAAP diluted EPS was $0.18 per share and non-GAAP diluted EPS was $0.36 per share. Fully diluted shares declined by $13 million, down 6 % year-over-year to 188 million shares outstanding. Our balance sheet and cash flow generation remained strong.

0:12:08

We ended Q2-27 with $713 million in cash, cash equivalents, and marketable securities, and we remained debt-free. We generated $91 million of free cash flow, outpacing adjusted EBITDA and up from $40 million in Q1. As expected from last quarter, collections activity normalized. During the quarter, we repurchased $54 million of shares. We believe share repurchases remain an attractive, opportunistic use of capital. As of September 30th, we had approximately $347 million remaining in our existing repurchase program.

0:12:44

Let's turn to our outlook. For revenue in Q3, we expect a range of $195 to $196 million, representing 6 % year-over-year growth at the midpoint. For FY27, we've raised our revenue guidance range to $678 to $683 million, also representing 6 % growth at the midpoint. We expect slight acceleration in second-half revenue growth versus first-half on a year-over-year basis. For FY27, we are increasing the guidance midpoint by $4.5 million. This reflects the flow-through of our Q2 outperformance, plus a modest incremental raise driven by growing visibility into the commercial AI pipeline.

0:13:27

AI Search is now an eight-figure bookings product, and we started recognizing revenue from the product when the first program launched in July. As a reminder, Q3 is our upfront season. This is when most pharma clients commit the majority of their marketing budgets for next year's programs and what are called upfront contracts. It is the largest bookings quarter of the year, and most contracts are signed by the end of December. We then typically recognize those commitments as revenue over the following 12 months, depending on the timing of program launches.

0:13:56

One key difference this year is the availability of our new AI Search product. To date, we've seen early broad-based adoption with 16 of the top 20 pharma companies having purchased programs, and three more are in our pipeline. We will provide an update about the upfronts and AI Search progress in our February call. In Q4, we expect year-over-year revenue growth to be similar to the Q3 guided growth rate. As with prior years, we have lower visibility into Q4 until we finish the upfront.

0:14:25

In addition, new products like AI Search have a steeper ramp in the first calendar quarter of a new year, so we help new customers through the medical legal review process. As a result, we expect a gradual ramp in AI search revenue throughout calendar 27. For adjusted EBITDA, in Q3 we expect a range of $102.5 to $103.5 million, representing a 53 % adjusted EBITDA margin at the midpoint. For FY27, we now expect a revised range of $317 to $325 million, representing a 47 % adjusted EBITDA margin at the midpoint.

0:15:01

This outlook incorporates the continued investment required to support the stronger-than-expected AI engagement we've seen this year. In the second half of FY27, we'll continue to invest in growing clinician AI usage and expanding our moats. Key initiatives include increased safety and accuracy through programs like DoseCheck, greater clinical content through partners like UpToDate, and growing distribution leadership with U .S. health systems. In closing, our long-term approach remains unchanged. We will continue to deliver one platform for AI clinical decision support, documentation, and patient communication.

0:15:38

Improving efficiency in our AI investments allows us to continue playing offense in the midst of this generational technology shift and help our clinicians be more productive so they can provide better care for their patients. Lastly, as a reminder, you can find our modeling considerations appendix in our prepared remarks where you can see more detailed financial commentary. And with that, I will turn it over to the operator for questions.

0:16:03
Operator

We will now begin the question and answer session.

0:16:06

Please limit yourself to one question and one follow-up. If you would like to ask a question, please press star 1 to raise your hand. To withdraw your question, press star 1 again. We ask that you pick up your handset when asking a question to allow for optimum sound quality. If you are muted locally, please remember to unmute your device. Please stand by while we compile the Q &A roster. Your first question comes from the line of Brian Peterson with Raymond James.

0:16:38

Brian, please go ahead.

0:16:40
Brian Peterson (Raymond James)

Hi, gentlemen. Thanks for taking the question. So, Jeff, I was encouraged by your comments on AI search, the eight-figure bookings, you know, 16 of the top 20 with more in the way. Maybe you could talk about how that kind of built over the course of this year versus your expectations, and is there anything qualitative that you could share about what that could do for your positioning into 2027?

0:17:04
Jeff Tangney (CEO)

Yeah, thanks, Brian. This is Jeff.

0:17:07

I'll say qualitatively, search is exciting to our clients and to us. We've had more what they call top-to-top meetings with hardware companies, chief marketing officers, or CEOs in the top 20. And they're going really well. It's an exciting time. They're getting real insight into the real problems that real patients and real doctors have without having to fly around and do lots of focus groups and rep rides and things that, frankly, aren't as efficient. So we're excited about that.

0:17:39

We think we're entering a whole new market here, which has historically been paid search. and I'll give a hat tip to Bank of America. They did a survey of 35 pharma marketers, completely independent survey. We had nothing to do with it. And they asked, if you had more incremental budget, more to spend on marketing, who would you spend more with? And we hit an all-time high with 81 % of the respondents saying they'd spend more with us.

0:18:13

And I think that's because of the traction we're seeing with our 190 health system partners and AI search growth. But interestingly, the group that fell the most there was with paid search or Google, which fell to only 6 % of the respondents saying that they would spend incrementally there. So I think that's proof that with AI search we are entering search budgets, which is about $14 billion a year in the United States, according to eMarketer, just for pharma.

0:18:42

So $14 billion a year spent on paid search. That is a much larger market than we have been in historically, and we're excited to enter it. So as I think of the build over the course of this year, I think we'll continue to see a big up front there. but starting early next year or late this year with a couple pilot clients, we'll also offer a binnable or auction-based purchasing there, which does make things a lot easier for our clients and for us.

0:19:17

And, again, brings us into an exciting whole new world that is more like paid search and less like endemic marketing.

0:19:24
Brian Peterson (Raymond James)

I appreciate the caller. And maybe just a follow-up. I wanted to hit on some of the AI compute things that you mentioned in terms of efficiency measures, in terms of multimodal usage or some of the performance gains from your hardest. Could you guys unpack that a bit? I know that's been a key topic of conversation with investors.

0:19:45
Jeff Tangney (CEO)

Thanks, Ben. Sure. Matt can speak to this a bit as well. I spoke at the Firework conference a couple days ago. There's a lot going on in AI inference right now, and most of it's good for companies like us in that there are just more options, and the platforms are getting more flexible to be able to handle, again, the security and medical needs that we have. We have a great team here. I will say I continue to be very pleased with the pathway acquisition and the new hires.

0:20:26

We've kept almost all of our AI teams to no turnover. So from our end, we're really excited about, again, all the new software tools that are allowing us to do our jobs better and helping doctors make better decisions at the point of care.

0:20:45
Matt Sonnenfeld (CFO)

Yeah, and I can just pile on a little bit. I think, honestly, the most important AI investment metric we have is just accelerated engagement, right? It speaks to us rapidly engaging with clinicians through ask, through scribe, through what is now the most accurate clinical AI product in the market.

0:21:07

So I think that's a good place for us to be, the accelerated engagement is the proof point. I think we're also getting better at learning how to develop with the infrastructure. And so all the things that we talked about in the prepared remarks, their performance on our proprietary harness, more multimodal deployments, buying more capacity in computer front, all of those things help. I think maybe my favorite financial metric from the quarter was our cost of revenue grew up less than half of our overall prompt volume in Q2.

0:21:38

And in Q1, those two things were pretty similar. Our cost of revenue grew at a much higher rate at a similar rate as prompt volume. So I think we've shown that we can be efficient as we deliver great results. Look forward to keeping that up.

0:21:55
Operator

Your next question comes from the line of Michael Cherney with Lee Rink Partners. Michael, please go ahead.

0:22:02
Michael Cherney (Leerink Partners)

Great. Thanks so much. Maybe just one, Jeff, here if I can. I'd love to get a little bit more detail on the up-to-date partnership.

0:22:11

The first time we've heard from you since that was announced, Walters Kluwer, clearly a well-regarded partner in the market. But how did you settle on that being the right partner at this point in time as you build out your AI capabilities? And as you think about what your other opportunities were, what else was the range of outcomes that landed here and landed at this being the right and the best partner at this point in time?

0:22:38
Jeff Tangney (CEO)

Thanks, Michael. Yes, we're excited. super excited to work with up to date. And, you know, they're picky. They're the number one player in the market, the most used, most trusted. I think Evercore ran a survey on this a little earlier this year. I mean, they're far and away head and shoulders above anyone else. I like to joke, IQIA like market share when it comes to being the clinical decision support point-of-care tool for doctors, most used, most trusted by far.

0:23:07

And like I said, they're choosy. So they've chosen to work with Epic, Microsoft, and us, and frankly not many others. And I think what we're bringing Greg and his team is a lot of AI savvy when it comes to being able to pull in broader, faster-moving evidence segments. But what they bring us, and uniquely in the market, is keep in mind, you know, everyone has access to all of the journals that are paid for largely by government grants and, you know, are all in the National Library of Medicine.

0:23:45

Everyone has access to all that, all the frontier models, but very, very few. I mean, none of the frontier models have access to up-to-date. So we're excited about that. We're just getting out in market with it now. It's been just a couple weeks since our announcement, but the client reaction to it has been very positive. And I would just say the partnership and the people also has been very synergistic. It's, you know, UpToDate is a mission-driven company, similar values to us and our team.

0:24:18

And, again, it seems to be just a strong synergy of, you know, our AI evidence tools and their unique expert opinion and physician expertise in that medical layer of knowledge that, frankly, isn't in a randomly controlled trial or published area. Final point note, we have significant customer overlap. They have 2,500 health systems as clients. We have, you know, 190. So we see a lot of overlap between our client base, and that also creates additional synergies for us.

0:25:00

So anyway, very excited about UpToDate, and you'll see more from us with them, you know, over the coming quarters. We're just getting started. Thanks, Craig. Yeah, that's a real milestone for us as a company. We have over half of all U .S. prescribers, and there are about 1.8 million U .S. prescribers, so about, you know, over 900,000 U .S. prescribers, and that's MD, DO, NP, or PAs, so folks who can legally write prescriptions in the U .S.

0:25:57

We have over half of them in the last quarter use our workload tools is a big milestone. We've never been that big before, and again, as we said, that's up 34 % year on year. So it's a good question. What's the biggest driver? The two biggest areas there are telehealth and scheduling. So telehealth continues to grow in this country. It's very popular, especially in disease categories like diabetes and, you know, let's face it, doctors are finding it's more efficient, and patients, of course, appreciate the no commute.

0:26:34

of being able to see your doctor virtually during the day. We're seeing a lot of doctors now have a half day or full day a week that is just dedicated to work-from-home telehealth, and we think that's better for doctors and their overall work-life balance and sanity. It's better for patients. We're really proud to help power it, and, again, we've never done as many telehealth calls as we did this last quarter. We're, again, seeing continued growth there kind of quietly.

0:27:02

You know, during COVID, we talked about telehealth a lot and that it sort of receded, but we're well above the call volumes that we were doing during COVID now, and so we're just seeing continued growth here in 23, 24, 25, 26. Scheduling also is a growth area for us. Doctors, of course, need to have their, you know, scheduled all their shifts. We make it easy to call each other, secure message them. So that's a continued growth area for us.

0:27:39

Those are the two I'd point to. The third, of course, is AI, which we've already been talking about a lot. But the reality is that's a whole new category of usage and growth for us. And I am particularly excited about the thousands of doctors we have now using the full patient context. So, you know, people don't want to go type the full patient history into a search bar. They want a suite, not a search bar, and that's what we offer them.

0:28:04

We offer them a suite, not a search bar. That suite allows them to do the tell-out visit, to have notes taken on that visit, what we call scribe, and then to ask questions about that visit with the patient context. Again, that's the most efficient way to get the best care in this country, and we're seeing that with that full patient context, there are already cases of tough diagnoses that probably would have taken a lot longer, right?

0:28:34

specialist visits and lots of follow-ups and AI is really very good at you know finding that that rare fast sonoma on page 89 and triangulating that into you know a patient that has a one in 100,000 disease so I know it's just so fulfilling for me that the my eyes get wide and frankly it's it's right to the core of our mission to help doctors again provide better care that patient contact in that suite and that AI growth which is over half of our workflow users those are the three big growth areas telehealth scheduling and AI search and Craig I think you asked a little bit as well about how that leads into a monetization opportunity and I

0:29:28

think I draw upon some of my experience in consumer web in particular at LinkedIn and like I think in those models and the same and business model that we have your engagement growth leads your monetization opportunity I like that we're building our engagement growth the right way based on workflow based on the value that we're adding for our clinician users and I'd be remiss if I didn't point out that a year ago our workflow active user growth was in the single digits.

0:30:00

Today, it's 34%. So, it's accelerated dramatically. I think that just gives us a pretty incredible opportunity over the next couple of years to grow our business as well. So, we're really excited about that.

0:30:12
Michael Cherney (Leerink Partners)

That's helpful context. Thanks. And then just as a follow-up, Matt, nice to see the upside to margins in the quarter and the guide. You pointed to some things in terms of efficiencies. As you kind of play this out, like, is there anything else you would point to in terms of perhaps building confidence of operating leverage in the business?

0:30:34
Matt Sonnenfeld (CFO)

Yeah. I think we talked a little bit about this in the last order earnings call where this is a matter of time sequencing, right? In order to drive that network engagement, the value for our users, that happens before you drive the monetization that follows it. And there is nothing about any of the AI investments and the early monetization we're seeing with AI search that would suggest that our margin profile would be dramatically different. Potentially, it could even be better over time, although it's not necessarily what we're over-optimizing for.

0:31:12

But I think more than anything else, we're really encouraged about the incremental margins that we'll see in the business as we really start to scale AI search in FY28 and beyond. Nothing gives us pause there, and revenue is going to be the ultimate thing that gives us the most leverage. I think some of the efficiency on the cost side just gives us more encouragement in that direction from this past quarter.

0:31:39
Michael Cherney (Leerink Partners)

Got it. Thanks.

0:31:40
Operator

Your next question comes from the line of Ryan Daniels with William Blair.

0:31:45

Ryan, please go ahead.

0:31:46
Ryan Daniels (William Blair)

Yeah, thanks for all the color and thanks for taking the question. Jeff, one for you, and you talked a little bit about this, but I want to dive a little bit deeper into it. With 16 of the top 20 pharma clients buying AI search solutions, are you able to tell if that's at all cannibalizing any of your other sales with them, or is it really all proving to be incremental at this point?

0:32:09
Jeff Tangney (CEO)

Yeah, it's a good question, Ryan I'd say it's mostly incremental Of course, it's impossible to know that exactly But I think we will know that exactly When we offer it as a biddable solution Where they're purchasing it Usually out of a separate team That is more of a search team Because it's more of a keyword-driven approach To marketing And that typically is a separate marketing team Within our clients So it's mostly incremental. I can't promise you it's 100 % incremental.

0:32:41

But I will say, going back to that survey of pharma marketers that was done, you know, we're proud to be at an all-time high, 81 % incremental spend. And I think that's mostly that paid search bucket that we are now entering, $14 billion a year spent on Google by pharma per year. And it is interesting in that same survey that Google is at an all-time low at 6%. So, again, mostly incremental. And the excitement to be able to really be in those highly relevant contextual places is something that we're excited about.

0:33:23
Matt Sonnenfeld (CFO)

Ryan, the only other thing I'll add, there was some of the language in the prepared remarks that you'll see around Q2. we saw positive growth in Q2 across all of our major product categories. And that's really encouraging. And while I think the doc, I'm sorry, why the AI search pipeline is continuing to grow, you know, it's still early days and pretty nascent. Most of what we're kind of seeing in the upfront cycle so far, again, early in the cycle is demand for our core products, whether it's in the newsfeed or it's, you know, video around, you know, Tyler and telehealth, I think we're in a good place with a solid foundation to build AI search on top of.

0:34:08

So I think that's encouraging for us, too, as we go throughout the year.

0:34:12
Ryan Daniels (William Blair)

Yeah, super helpful, Connor. And then, Jeff, as my follow-up, it seems like we're seeing a lot tighter governance among health systems, especially bigger ones or academics, about how doctors use AI. So, you know, early on, maybe just download a free tool, but now they're getting a lot more concerned about liability and patient care. And I'm curious how that plays into your advantage given the outcomes you've been able to present, like you talked about earlier, plus the massive channel distribution you have with your dialer asset into those enterprise accounts.

0:34:42

Thanks.

0:34:42
Jeff Tangney (CEO)

Yeah, thanks, Ryan. Yeah, I think on last quarter's call, you know, we had made some comments about, you know, AI accountability. That's the next age or next phase for our health system clients, which we did grow from 165 to 190, so 25 new clients in the last quarter. And we are going to keep growing there. We have over 300 enterprise clients overall on our telehealth and other products. And we have privacy agreements in place with all of them, but we don't have the AI review with all of them.

0:35:20

But that 300 enterprise clients that we have are nearly half of all U .S. physicians. So we cover all the largest health systems. And, again, that's where we really see this AI growth in CAM. One specific case that came out this last week was Johns Hopkins. They had 3,000 patients that they had to send an e-mail out to, which isn't fun for anyone to do, telling them that an employee had uploaded some of their data to an unapproved AI.

0:35:54

So when we see things like that happen and we've seen a bunch of other health systems put in IP-level blocks, I think we're just going to see more of that happen because the reality is people should be concerned about the security of their patient data being put into AI that may leak out in various places. So I think we're moving beyond the Wild West phase of AI and health systems. We're proud to announce NYP this quarter as a new AI logo.

0:36:34

We're trying to announce UCSD, both top 20 hospitals, as a new logo. But I do think you're right. I think we're entering this new phase here where hospitals, I think, will rightfully start to say, okay, what kind of data might we be leaking? And what sites, frankly, do we need to block? They've done that for years and years. It's not a new thing for them. I think they've just been catching up on how much that AI leakage might be happening.

0:37:12
Ryan Daniels (William Blair)

Yeah. Okay. Super insightful.

0:37:14
Operator

Your next question comes from the line of Elizabeth Anderson with Evercore ISI. Elizabeth, please go ahead.

0:37:20
Elizabeth Anderson (Evercore ISI)

Hi, guys. Good afternoon. Thanks so much for the question. Obviously, you talked about the 16 of the top 20 customers, or pharma customers, in terms of the three of the pipeline. Can you talk to us about the smaller customers? Are they also kind of in the same, you know, are they a little bit more reticent or they're just smaller?

0:37:42

And sort of how do we think about the typical ramp of some of these buying? Are they kind of trying it out first and then sort of with future expansion plans in 27, if that goes well? Are they jumping right in? And just a little bit more color on how you see those two segments progressing over the next few quarters to year would be very helpful.

0:38:03
Jeff Tangney (CEO)

Great. This is Jeff. I'll take a first crack with a hand to Matt here.

0:38:08

The short answer is, you know, we know that the medical legal review processes of the top 20 pharma are intensive, and we wanted to start there. So we started at the top, if you will, at the most difficult place. And that's been going well. It does take time. Obviously, we have to, you know, go through and understand, you know, suppression keywords and keywords and where things appear. And, you know, there's a lot of testing and all that.

0:38:37

But it's all part of the process. And, again, we proudly work with, you know, this will be 19 of the top 20 pharma with the three we have in contracting. In terms of smaller accounts, actually things move faster there. But generally speaking, we haven't focused as much on selling to that audience because we think they're going to be the perfect clients for our new auction or biddable tool. And that will be, you know, less – a more efficient go-to-market motion for those smaller accounts.

0:39:15

We started with our more strategic, bigger accounts, which is what we typically do. Again, our best new products go to our best or biggest clients first. But, Matt?

0:39:25
Matt Sonnenfeld (CFO)

I actually don't know if I have that much more to add. I think probably one of the things that signals well is one of the data points when we prepare to Marks, which is that based on customer demand, we've made available kind of more than double what we started with in terms of available conditions.

0:39:45

And that really just speaks to, I think, a broad set of places that pharma customers are interested in, conditions, drug areas, different types of treatments. You'll see that there's just a lot of interest here. And Jeff's point, AI search is going to become a lot more accessible as we move into FY28. So we're excited. We're encouraged. I think the demand is there as we just continue to ramp it up.

0:40:17
Elizabeth Anderson (Evercore ISI)

Yep, that makes a ton of sense.

0:40:20

Thanks for all the additional color.

0:40:22
Operator

Your next question comes from the line of Ryan McDonald with Needham & Company. Ryan, please go ahead.

0:40:29
Ryan McDonald (Needham & Company)

Hi, thanks for taking my question. Congrats on the quarter. Jeff, as we think about the example you provided with New York Presbyterian now providing access to the AI solution directly through the EHR. Once that occurs within your health system client, what impact do you see or what kind of uplift do you see on usage?

0:40:51

And then how important has that sort of uplift or that EHR integration been as you've been going to market with the AI search product?

0:41:01
Jeff Tangney (CEO)

Great, Ryan. Yeah, thanks. I will say that with our patient context doctors or clients, we've seen roughly a doubling in the amount of usage. Even though they're able to type less themselves because they have more patient context coming in, there's a big time savings there. And, again, I think that's really the future is, you know, your doctor will be sitting there with you in a visit, and, you know, the AI will be there with him or her, and it will have, again, your history there so that nothing gets missed.

0:41:40

And that's really a very exciting future. With regard to just, you know, turning on within an EHR, we've done that in lots of places. I've got to be honest, the truth is just putting a button inside an EHR does not, in and of itself, get immediate usage. You actually have to do a bit of training and webinars. Maybe this is a sad statement on electronic health records, but, you know, a lot of doctors are trained not to click a button if they haven't been trained on it.

0:42:14

And there's just a lot of that sort of hefty behavior around trying out new features or new things inside some of these systems, which have lots of cul-de-sacs and strange behaviors. So we're good at that. Again, we've been working with them for years, usually, as a partner on telehealth and scheduling. and it's actually been fun for our team to have, you know, our monthly Zoom call be about a whole new series of features and products.

0:42:50

And I think we've got many months of good Zoom calls there with our clients to help them see all the things they can do with it. But short answer is patient context does lead to an immediate lift, but just being inside an EHR less than you might think.

0:43:08
Ryan McDonald (Needham & Company)

That's helpful, Co. I appreciate that. Maybe just as a follow-up, as you think about sort of expanding that top-down penetration within the health systems, how valuable do you think the up-to-date partnership can be?

0:43:21

And is there any sort of go-to-market sort of relationship there where they can help bring you into, obviously, that very large customer base that they have? Thanks.

0:43:32
Jeff Tangney (CEO)

Thanks, John. You're absolutely right. Up-to-date is, you know, virtually everywhere in the U .S. health system. And as I said, our teams have been getting along great. We think that, again, they're just a very high integrity, you know, real boom for the overall health system. So we're proud to work with them, and we hope and expect to keep expanding our relationships.

0:43:58

I don't have anything to announce today on go-to-market with them, but that's some of the things that have been discussed. but let's just say that I think it's the beginning of what we think will be a very strategic, very, it's a long-term partnership, multi-year. We're excited to keep going with them.

0:44:20
Ryan McDonald (Needham & Company)

Awesome. Thank you.

0:44:21
Operator

Your next question comes from the line of Scott Schoenhaus with KeyBank. Scott, please go ahead.

0:44:28
Scott Schoenhaus (KeyBanc)

Hey, guys. Thanks for taking my questions.

0:44:31

I just wanted to follow up on Elizabeth's question. I just wanted to make sure I understood how long does a typical medical legal review process take, and how should we think about that ramp in AI search revenues after you clear that process? Is it very back half-weighted in calendar 27?

0:44:51
Jeff Tangney (CEO)

This is Jeff. I'll chime in first. I mean, for new products, MLR review can be months and months, And we learned this, candidly, the hard way back with our vertical video product, as you may recall, a few years ago.

0:45:07

And, you know, we had a lot of signed contracts, but we didn't have the revenue coming in for a many-month gap because video, honestly, is difficult for lawyers to review well. and there's lots of tools and processes that need to be put in place to be able to comment on frame 68 or 25 seconds in. I think we're being appropriately cautious here in our time frames, and we're assuming that it will also take many months to get live with these contracts.

0:45:49

So that does lead to, again, I think, again, a cautiously optimistic approach to the rest of this fiscal year.

0:45:56
Matt Sonnenfeld (CFO)

I'll add a couple of points. I think one is that I think you see that assumption on that gradual ramp, especially kind of just from a calendar year 27 standpoint in our guidance, right? Our growth rate in Q4 is very similar to our growth rate in Q3. And part of that is because we know that, especially for customers that are buying AI search for the first time, there will be that ramp up that just described in terms of the MLR process.

0:46:28

I would say, you know, in terms of some of our early upfront activity, a lot of the AI search contracts kind of assume that too, right? It will be a ramp up throughout the next calendar year. So that's a dynamic that we're seeing as well. I don't think any of that is surprising based on what Jeff described about some of our past product cycles. But that's kind of what the assumptions are that we're making for our business.

0:46:54
Scott Schoenhaus (KeyBanc)

Perfect. Thanks, Matt. And just as a follow-up, so that 6 % growth rate for 3Q and then for 4Q, which we start into the next calendar year, typically people read that as a reflection of your view of what maybe the market can grow at or what you can grow at. How should we view that in context of what you're viewing the market growth at as you've outlined 6 % growth into the calendar new year? Thanks.

0:47:20
Matt Sonnenfeld (CFO)

Yeah, I think it reflects, you know, the beginnings of reacceleration in our business, right? I provided the comment that our second half, our fiscal second half outlook has slight acceleration versus our first half. I think that's where you see the beginnings of optimism for us as we look into next year. At the same time, you know, it's early. We're not through our upfront cycle yet. And so I think we want to be thoughtful, you know, especially as we think about kind of fiscal Q4 and calendar Q1, see how the upfront lands, also know that some of the AI search demand in particular will ramp throughout the year.

0:47:58

but I think we're pretty encouraged and optimistic as we sit here today in November for future growth.

0:48:05
Jeff Tangney (CEO)

Scott, I'll just add on the market itself, I think there's some cautious optimism that hopefully next year is better than this year. This year was a perfect storm of a lot of different things not going the market's way. And so I think there's some reasons to be a little more optimistic for next year.

0:48:26
Operator

Thanks, Scott. The next question comes from the line of Richard Close with Canaccord Genuity.

0:48:32

Richard, please go ahead.

0:48:34
Richard Close (Canaccord Genuity)

Yeah, thanks. Congratulations on the report and the AI progress. So, Jeff, for Matt, just given the comments that AI may be additive and a different buyer, I'm curious, do you have separate sales force going after this, or, you know, is it the same account teams as the other products? And then with respect to the upfront contracts that you're working on now, is AI bundled in, or is that, you know, completely separate since it's a different budget, possibly?

0:49:19
Jeff Tangney (CEO)

Hey, Richard, this is Jeff. Right now we have an overlay, we call it, but basically a team approach where we have some new experts we have in the AI search who join our sales team in, you know, leading with some of these search budget holders. And right now the contracting, I mean, we typically have, you know, these master service agreements, and then we have these statements of work they've called. Sometimes they're together on the same statement of work.

0:49:48

Usually I think it's a separate statement of work. But again, this is the advantage of being a reference client, someone who's already vertically working with all of the top 20 pharma. It's been relatively low overhead for us to add on this search AI business to existing clients.

0:50:12
Richard Close (Canaccord Genuity)

Okay, thank you.

0:50:13
Operator

Your next question comes from the line of Jessica Tadson with Piper Sandler. Jessica, please go ahead.

0:50:22
Jessica Tadson (Piper Sandler)

Hi, guys. Thank you very much for the question. And congrats on New York Presby and the 25-plus new AI hospital wins.

0:50:33

So as you guys have started to deploy AI search, including patient contacts, in these enterprise contracts and commercialize the AI search offering via pharma bookings, Can you help us understand how you're monetizing this product? Basically, you know, what the eight-digit bookings consist of. Are those enterprise subscriptions or pharma bookings or both? You know, what I'm trying to get at is just in these enterprise contracts, is AI search exclusively monetized via subscription revenue? So, ostensibly, for those 190 clients, you know, it might hit at day one.

0:51:03

And then is pharma revenue kind of exclusively generated from independent physicians or physician practices using Doximity Ask? any color there on just how exactly these AI products are being monetized would be super helpful.

0:51:18
Matt Sonnenfeld (CFO)

Hey, Jess, this is Matt. Thank you for the question. It's a good one. I would say the primary way we're monetizing and when we talk about eight-figure bookings, it's primarily with our pharma customers and selling AI search as an advertising product. We do sell AI as a separate enterprise agreement to health systems customers.

0:51:41

We charge a nominal amount as part of our broader workflow suite. And so I think as we think about this going forward, we see the primary monetization engine being on the pharma side of our business, specifically through the ad products that we sell.

0:51:57
Jessica Tadson (Piper Sandler)

Okay, that's great. That's extremely helpful. And then just any early thoughts on ROI for the pharma educational content displayed in AI search relative to Doximity's core business? I think, Matt, you mentioned most of the early upfront bookings are core Doximity, so does that imply kind of parity ROI?

0:52:16

Just interested in any early thoughts on ROI for the educational content in AI search. Thanks again, guys.

0:52:22
Matt Sonnenfeld (CFO)

Hey, Jess, I think the answer is it's just too early. A lot of these programs just launched in the last few months. That being said, this is the most contextually-alding product we have. And so I think the working thesis is give us a few more months, we'll have more kind of results in. But this should be just as, I would say, ROI strong as the other products, if not better.

0:52:44

And the right thing is this is also making all of our product portfolio better. There's AI signal now in other products. You know, when you buy AI search, you're not just buying media. You're buying, you know, insights. you're buying retargeting the other parts of the platform. And so everything gets better. Everything gets a better education at the right time to the right docs. So I think the longest road is it's a little too early right now, but the thought is it'll be just as good, if not better.

0:53:12
Operator

Your next question comes from the line of Alexei Gogolov with JPMorgan. Please go ahead, Alexei.

0:53:18
Destiny Jackson (JPMorgan)

Hi, this is Destiny Jackson on for Alexei Gogolov. I wanted to touch on NRR. saw that it moved down for overall to 103 % and to 106 for top 20. Keith Hatchman was driving that trend down and what are the levers to recalorate expansion?

0:53:37
Matt Sonnenfeld (CFO)

Hi, Destiny. Thanks for the question. The, I would say those metrics tend to follow our revenue growth and I think we see that as being at a cross level.

0:53:49

Like we said, we're expecting the beginnings of reacceleration in the second half. Usually those metrics follow the rate of revenue growth. Also, I would say, you know, as we move forward, and something I kind of am thinking about, you know, as a newer person in my seat, I think these metrics may not be the right set of metrics to measure our growth going forward. I'll take the customer count one as an example. It's very focused on our largest customers that we've landed and had in place for a long time.

0:54:21

It misses our small and medium growth segment, which has been one of the faster-growing segments for several quarters now within our pharma business. So I think, you know, we'll see and evolve the right metrics for our next chapter of growth, but it's not something I'm particularly worried about as, you know, we consider the opportunities that are sitting in front of us over the next several quarters.

0:54:43
Jeff Tangney (CEO)

Definitely, I'd just add on the reacceleration point. I think there's three things you can look at.

0:54:50

One of them is just AI search, new incremental. We're getting deeper, better breadth of all of our customers, even the existing ones in particular. The core of the other products have higher value because of the search signal. There's more excitement around just the whole portfolio than we've seen in a while. And then, you know, my earlier comment, cost optimism in the market itself will be a little bit better, at least a little bit better next year than this year.

0:55:12

So I think all three of those could contribute to, you know, improving NRR as we go forward.

0:55:20
Destiny Jackson (JPMorgan)

And then as a follow-up, the customer count for the customers over 500,000, that came down for 2Q, 2Q, which I saw on what drove that acceleration.

0:55:30
Matt Sonnenfeld (CFO)

And, Betsy, I'm going to have you repeat the question again. I just sounded a little garbled on our end.

0:55:38
Destiny Jackson (JPMorgan)

Sorry. It was on the customer count for 500,000 customers. It came down this quarter, so this one had even covered it.

0:55:48
Matt Sonnenfeld (CFO)

Oh, right. So Q2 is actually usually one of the weaker quarters for that metric, just from an expanded standpoint. You just see less kind of incremental upsell activity. That's basically what I would point to if you look at past quarters and past Q2s and past years, you see a kind of similar pattern of relative seasonal weakness. That's the primary explanation for that.

0:56:17
Operator

Your next question comes from the line of Alan Lutz with Bank of America. Alan, please go ahead.

0:56:27
Alan Lutz (Bank of America)

Good afternoon, and thanks for taking the question. First, Jeff, thanks for the shout-out on the survey. Really appreciate that. Can you talk a little bit about the evolution of the competitive landscape here in AI search? You're looking at really two very different markets in your traditional pharma customer and then the health system customer. I would love to get a sense of how the competitive landscape in each is evolving over time.

0:56:55
Jeff Tangney (CEO)

Thanks, Alan, and I appreciate you listening to the shout-out.

0:57:00

I'd say I've reluctantly come to like your survey because it is, you know, 35 pharmaceutical marketers, which is good coverage given the top 20 is most of the market. and you do do a good job of adding in all the various companies or partners that they work with. You know, your chart there pointed it out, I think, pretty clearly. We're at the highest level there of interest in incremental dollars we've ever had. Paid search or Google is at the lowest level it's ever been, and some of the new search players there have also dipped, as I think, you know, again, and there are ups and downs in the market, and some folks are pleased with their partnerships and some are

0:57:48

not. So I guess my short answer to your question is that I think you are pointing us to the fact that these really are two different markets. One is search, and one is media. And the good news is we're really expanding. A year ago, we were a pure media company, and now we are a media company. and a search company, and as Perry pointed out a few moments ago, there's a lot of synergy between the two because the reality is Google, knowing that you search X here, means that they're better able to target you on YouTube there.

0:58:25

And those two things go together very well, and that's what we see with our business, our telehealth, which, again, is at all-time highs, our scheduling, our other workflow tools in addition to AI search.

0:58:39
Alan Lutz (Bank of America)

Appreciate that, Tyler. And then one for Matt, the margins in the quarter were really strong, and you talked a little bit in the Q &A around some of the operating levers you could see in the business. We'd love to get a sense of are there opportunities to invest where it would be a high ROI investment, and how do you think about investing more in things like AI surge versus maintaining these margins north of 50%?

0:59:12
Matt Sonnenfeld (CFO)

Yeah, and I think you see us making that conservative investment in our EBITDA margin for the full year. I think we have what we feel like is the right firepower to be able to make some of these incremental investments. We literally look at things that we can do differently on a week-in and week-out basis, especially right now, given it such a dynamic time. And that's led us to kind of, I think, continue to iterate on the infrastructure that we're using, begin to make investments like in the auction biddable product that Jeff was describing earlier, kind of play offense through some of these partnerships.

0:59:52

We'll continue to do that. I think what you also see is that we have a really great business model as a company. It generates really incredible incremental margins, especially when we outperform from a revenue standpoint. And we have a really great team who excels at executing. I think you saw that this quarter again. I'll share the metric I shared earlier in the Q &A, which is this quarter, our cost of revenue, which is highly AI-focused right now, grew at half of the rate of our prompt volume in our AI products, whereas last quarter those things were one-to-one.

1:00:33

So we saw from that measure kind of a 50 % efficiency on our incremental spend. And that is just a huge, huge kudos and credit to our team who continues to innovate on AI infrastructure. So we'll continue to play offense, very much so, but I'm also pretty confident in our ability to generate great incremental margins as we're doing it. Great.

1:00:57
Operator

Your last question comes from the line of Ryan Halstead with RBC Capital Markets. Ryan, please go ahead.

1:01:06
Ryan Halstead (RBC Capital Markets)

Thanks for squeezing me in and taking my question. And any perspectives you can offer on just the general health of HCP marketing budgets going into the upfront season? You know, just seeing a lot of biopharma activity, you know, lots of new drug approvals. Just curious if, you know, how you're seeing HCP marketing budgets so far.

1:01:30
Matt Sonnenfeld (CFO)

I can take a first crack at it. This is kind of my first go around in this seat. here at Doximity and kind of thinking through the upfront.

1:01:42

And my, you know, as I go through it and I compare it to a lot of the team's experience last year, I think it feels like a more stable environment. I wouldn't say it's world beating or having a massive growth uplift. I think there are some dynamics in terms of pharma approval pipelines that are improving. And whereas last year there was a lot of policy uncertainty and friction, I think that is stabilizing, although I wouldn't say, you know, it's kind of up and to the right.

1:02:14

And so I think it feels like a more stable, a more comfortable environment to do business in, but not necessarily one that's dramatically reaccelerating from a macro standpoint.

1:02:24
Jeff Tangney (CEO)

Yeah, this is Jeff. I'll just add, you know, if you look at the iShares Pharma ETF, it's up about 40 % year on year. And you think about where we were a year ago compared to today. Again, there were a lot of negotiations around price and tariffs, and there's just a lot of things in the mix that I think we look at this year as a more stable environment for us to grow and, you know, do our jobs.

1:02:59
Operator

There are no further questions at this time. I will now turn the call back to CEO Jeff Tangney for closing remarks.

1:03:09
Jeff Tangney (CEO)

I'd like to end by thanking the entire Doximity team for the hard work serving more doctors every day than ever before. So thank you everyone for joining. This concludes today's call. Thank you for attending. You may now disconnect.